Cardiovascular therapies and risk for development of diabetes

Journal of the American College of Cardiology

Volumn 44, Issue 3, 2004, Pages 509-512

  Pepine, Carl J ^a   Cooper Dehoff, Rhonda M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

ACE; angiotensin receptor blocker; angiotensin converting enzyme; ARB; BB; beta blocker; CA; CAD; calcium antagonist; cardiovascular; coronary artery disease; CV; HCTZ; Heart Outcomes Prevention Evaluation; HOPE; hydrochlorothiazide; SCOPE

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; PINDOLOL; RAMIPRIL; TRANDOLAPRIL; VERAPAMIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR PROCEDURES; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; INCIDENCE; OUTCOMES RESEARCH; PATIENT; PHYSICIAN; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; DIABETES MELLITUS; DIURETICS; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RISK FACTORS; UNITED STATES;

EID: 4043124049     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.03.071     Document Type: Review

References (29)

1. Morrish N.J., Wang S.L., Stevens L.K., Fuller J.H., Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 44:(Suppl 2):2001;S14-S21
2. Executive summary. United States Renal Data System 1999 Annual Data Report. Am J Kidney Dis. 34:(Suppl 1):1999;S9-19
3. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus Atherosclerosis Risk in Communities Study. N Engl J Med. 342:2000;905-912
4. Suter P.M., Vetter W. Metabolic effects of antihypertensive drugs. J Hypertens Suppl. 13:1995;S11-S17
5. Lithell H.O. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 14:1991;203-209
6. Mykkanen L., Kuusisto J., Pyorala K., Laakso M., Haffner S.M. Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects. J Hypertens. 12:1994;1425-1432
7. Kohner E.M., Dollery C.T., Lowy C., Schumer B. Effect of diuretic therapy on glucose tolerance in hypertensive patients. Lancet. 1:1971;986-990
8. The Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Hypertension. 7:1985;1008-1016
9. Samuelsson O., Hedner T., Berglund G., Persson B., Andersson O.K., Wilhelmsen L. Diabetes mellitus in treated hypertension Incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens. 8:1994;257-263
10. Holzgreve H., Nakov R., Beck K., Janka H.U. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens. 16:2003;381-386
11. Tatti P., Pahor M., Byington R.P., et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 21:1998;597-603
12. Pollare T., Lithell H., Morlin C., Prantare H., Hvarfner A., Ljunghall S. Metabolic effects of diltiazem and atenolol Results from a randomized, double-blind study with parallel groups. J Hypertens. 7:1989;551-559
13. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension The Captopril Prevention Project (CAPPP) randomised trial. Lancet. 353:1999;611-616
14. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 354:1999;1751-1756
15. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342:2000;145-153
16. Brown M.J., Palmer C.R., Castaigne A., et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 356:2000;366-372
17. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) A randomised trial against atenolol. Lancet. 359:2002;995-1003
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 288:2002;2981-2997
19. Reid C.M., Johnston C.I., Ryan P., Willson K., Wing L.M. Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics Findings from the 2nd Australian National Blood Pressure Study. (abstr) Am J Hypertens. 16:2003;11A
20. Lithell H., Hansson L., Skoog I., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE) Principal results of a randomized double-blind intervention trial. J Hypertens. 21:2003;875-886
21. Lindholm L.H., Persson M., Alaupovic P., Carlberg B., Svensson A., Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 21:2003;1563-1574
22. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure The CHARM-Overall programme. Lancet. 362:2003;759-766
23. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST) A randomized controlled trial. JAMA. 290:2003;2805-2816
24. Hansson L., Hedner T., Dahlof B. Prospective randomized open blinded end-point (PROBE) study A novel design for intervention trials. Prospective Randomized Open Blinded End Point. Blood Press. 1:1992;113-119
25. Narayan K.M., Boyle J.P., Thompson T.J., Sorensen S.W., Williamson D.F. Lifetime risk for diabetes mellitus in the United States. JAMA. 290:2003;1884-1890
26. Lindholm L.H., Hansson L., Dahlof B., et al. The Swedish Trial in Old Patients with Hypertension-2 (STOP-Hypertension-2) A progress report. Blood Press. 5:1996;300-304
27. Cooper-DeHoff R.M., Bakris G.L., Cohen J.D., Messerli F.H., Erdine S., Pepine C.J. Reduced risk of new onset diabetes in hypertensive coronary artery disease patients treated with a calcium antagonist vs a beta blocker regimen The INternational VErapamil/trandolapril STudy. (abstr) Circulation. 108:(Suppl IV):2003;IV750
28. Lindholm L.H., Ibsen H., Borch-Johnsen K., et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 20:2002;1879-1886
29. Verdecchia P., Reboldi G., Angeli F., et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 43:2004;963-969